Celldex Therapeutics (CLDX) vs IDEXX Laboratories (IDXX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Celldex Therapeutics (CLDX) has outperformed IDEXX Laboratories (IDXX) over the past year, gaining 7.6% versus a loss of 18.5%. Over five years, IDXX leads with a -19.2% price change compared with -36.6% for CLDX. IDEXX Laboratories is the larger company by market cap ($40.81 billion vs $2.35 billion), about 17.4 times the size.
IDEXX Laboratories converts more of its revenue into profit, with a net margin of 24.6% versus -16748.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDX | IDXX |
|---|---|---|
| Share price | $29.89 | $518.00 |
| Market cap | $2.35B | $40.81B |
| 1-day change | +2.01% | +0.95% |
| YTD return | +7.88% | -24.15% |
| 1-year return | +7.56% | -18.54% |
| 5-year return | -36.55% | -19.21% |
| P/E ratio (TTM) | — | 36.40 |
| Forward P/E | — | 30.95 |
| EPS (TTM) | $-4.35 | $14.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54M | $4.30B |
| Revenue growth (YoY) | -77.99% | +10.42% |
| Net income (latest FY) | $-258.76M | $1.06B |
| Gross margin | 87.06% | 61.80% |
| Operating margin | -18599.81% | 31.60% |
| Net margin | -16748.03% | 24.62% |
| 52-week high | $45.14 | $769.98 |
| 52-week low | $22.10 | $500.61 |
| Distance from 52-week high | -33.78% | -32.73% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +111.01% | +35.39% |
| Average volume | 1.32M | 553.95K |
| Shares outstanding | 78.53M | 78.78M |
| Employees | 198 | 11,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IDEXX Laboratories is about 17.4 times larger than Celldex Therapeutics by market value ($40.81B vs $2.35B).
- CLDX has outperformed IDXX by 26.1 percentage points over the past year.
- IDEXX Laboratories is more profitable, keeping 24.6 cents of every revenue dollar as net income versus -16748.0 cents for Celldex Therapeutics.
- IDEXX Laboratories grew revenue faster in its latest fiscal year (+10.42% vs -77.99%).
About Celldex Therapeutics
CLDX stock →Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 198 employees
About IDEXX Laboratories
IDXX stock →IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 11,000 employees
CLDX vs IDXX FAQ
Which is bigger, Celldex Therapeutics or IDEXX Laboratories?
IDEXX Laboratories (IDXX) is larger, with a market capitalization of $40.81B compared with $2.35B for Celldex Therapeutics (CLDX).
Which stock has performed better over the past year, CLDX or IDXX?
CLDX returned +7.56% over the past 12 months, compared with -18.54% for IDXX (price return, excluding dividends). Past performance does not predict future results.
Are Celldex Therapeutics and IDEXX Laboratories in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.